Drug General Information (ID: DDIFQ0K8HL)
Drug Name			Interferon beta-1b		Drug Info		Cladribine		Drug Info
Drug Type		Interferons				Small molecule
Therapeutic Class		Immunomodulatory Agents				Antineoplastics

Mechanism of Interferon beta-1b-Cladribine Interaction (Severity Level: Moderate)
Additive myelosuppressive effects Click to Show/Hide Mechanism Graph
Drug Name		Interferon beta-1b				Cladribine
Mechanism		Myelosuppressive effects Risk of lymphopenia				Myelosuppressive effects Risk of lymphopenia
Key Mechanism Factor 1
		Factor Name		Myelosuppressive effects
		Factor Description		Myelosuppression, also known as bone marrow suppression, is a decrease in bone marrow activity that leads to a decrease in the production of blood cells. Some blood cell disorders include: erythrocytopenia (anemia), leukopenia (neutropenia), and thrombocytopenia (thrombocytopenia).
Mechanism Description		Additive myelosuppressive effects by the combination of Interferon beta-1b and Cladribine

Recommended Action
Management		Concomitant use of cladribine and beta interferons is not recommended.

References
1	Cerner Multum, Inc. "Australian Product Information.".
2	Product Information. Leustatin (cladribine). Ortho Biotech Inc, Raritan, NJ.
3	Montalban X, Leist TP, Cohen BA, et.al "Cladribine tablets added to IFN-a in active relapsing MS: The ONWARD study." Neurol Neruroimmunol Neuroinflamm 11 (2018): e477